BioDrugs
Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence
Ira Jacobs*, Reginald Ewesuedo, Sadiq Lula, Charles Zacharchuk
**Corresponding author:* Ira Jacobs; Pfizer Essential Health, Pfizer Inc, 235 East 42nd Street, New York, NY, 10017-5755, USA.
Email: ira.jacobs@pfizer.com

Supplementary Table S5. A summary of non-empirical publications included in the review

Authors/country	Type of review	Summary
Ebbers et al. (2013) [1]	Biosimilar development	Describes measures of demonstrating biosimilarity for monoclonal antibodies using bevacizumab as an example
da Silva et al. (2012) [2]	Biosimilar development	Discusses approach for the characterization and development of a high-quality biosimilar monoclonal antibody using rituximab as an example
Kurbanova et al. (2012) [3]	Manufacturing/supply	Review of aspects associated with production of biopharmaceuticals
Li et al. (2015) [4]	Manufacturing/supply	Review of aspects associated with production of biopharmaceuticals
Beck et al. (2012) [5]	Quality/analysis methods	Analytical discussion regarding characterization of therapeutic antibodies by mass spectrometry within the context of trastuzumab and cetuximab
Nelson et al. (2014) [6]	Economics/pricing	Discusses development of biosimilar trastuzumab products
Dhingra (2009) [7]	Therapy area overview	Provides industry perspective on biosimilars
Cragg (2011) [8]	Therapy area overview	Discusses development of biosimilars of CD20 antibodies
Rioufol and Salles (2015) [9]	Therapy area overview	Discusses development of biosimilars of CD20 antibodies
[None listed] (2013) [10]	General overview	Provides description of biosimilars and their potential role in healthcare
Vital et al. (2013) [11]	General overview	Description and opinion of rituximab biosimilars
Thill (2015) [12]	Regulation/policy	Reviews current state of biosimilar monoclonal antibodies for the treatment of breast cancer
Kay (2011) (USA) [13]	Regulation/policy	Reviews regulatory aspects of biosimilar development in America
Kudrin et al. (2015) [14]	Regulation/policy	Describes clinical and regulatory evaluation of biosimilar monoclonal antibodies using case studies

References

1. Ebbers HC, et al. Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab. Drug Discov Today. 2013;18(17-18):872-9. doi: 10.1016/j.drudis.2013.05.004. **2.** da Silva A, et al. Comprehensive target-directed approach for the development of a highly-comparable rituximab biosimilar. Ann Rheum Dis. 2012;71(suppl 3):718. doi: 10.1136/annrheumdis-2012-eular.1395. **3.** Kurbanova EK, et al. PHARMA-2020: technological aspects of production of some strategical biopharmaceuticals. J Biopharm. 2012;4:21-45. **4.** Li E, et al. Development of biosimilars in an era of oncologic drug shortages. Drug Des Devel Ther. 2015;9:3247-55. doi: 10.2147/dddt.s75219. **5.** Beck A, et al. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. Anal Chem. 2012;84(11):4637-46. doi: 10.1021/ac3002885. **6.** Nelson KM, Gallagher PC. Biosimilars lining up to compete with Herceptin – opportunity knocks. Expert Opin Ther Pat. 2014;24(11):1149-53. doi: 10.1517/13543776.2014.964683. **7.** Dhingra K. Biosimilars: the industry perspective. J Crohns Colitis. 2009;3(suppl 1):78. **8.** Cragg MS. CD20 antibodies: doing the time warp. Blood. 2011;118(2):219-20. doi: 10.1182/blood-2011-04-346700. **9.** Rioufol C, Salles G. Biosimilar monoclonal antibodies in lymphoma: a critical appraisal. Expert Rev Anticancer Ther. 2015;15(5):569-78. doi: 10.1586/14737140.2015.1028919. **10.** What are biosimilars and are they important? Drug Ther Bull. 2013;51(5):57-60. doi: 10.1136/dtb.2013.5.0181. **11.** Vital EM, et al. Rituximab biosimilars. Expert Opin Biol Ther. 2013;13(7):1049-62. doi: 10.1517/14712598.2013.787064. **12.** Thill M. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer. Expert Rev Anticancer Ther. 2015;15(3):331-8. doi: 10.1586/14737140.2015.993318. **13.** Kay J. Biosimilars: a regulatory perspective from America. Arthritis Res Ther. 2011;13(3):112. doi: 10.1186/ar3310. **14.** Kudrin A, et al. Case studies on clinical evaluation of biosimilar monoclonal antibody: scientific considerations for regulatory approval. Biologicals. 2015;43(1):1-10. doi: 10.1016/j.biologicals.2014.11.002.